Digest Network Come funziona
Network
/
Società
OK
Non verificato

OKYO Pharma LTD

Di cosa scriviamo

Annunci EconomiciBiotecnologiaFinanzaFondi di investimentoMedicina Salute Benessere

8 comunicati stampa

Guarda tutti i comunicati
23/02/2026
Biotecnologia
Medicina Salute Benessere
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
Fonte
OKYO Pharma LTD
Emittente
GLOBENEWSWIRE
1.00
0
12/02/2026
Biotecnologia
Finanza
Medicina Salute Benessere
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
Fonte
OKYO Pharma LTD
Emittente
GLOBENEWSWIRE
1.00
0
12/02/2026
Biotecnologia
Fondi di investimento
OKYO Pharma Announces Public Offering of Ordinary Shares
Fonte
OKYO Pharma LTD
Emittente
GLOBENEWSWIRE
1.00
0
11/02/2026
Biotecnologia
Management/Organizzazione Aziendale
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
Fonte
OKYO Pharma LTD
Emittente
GLOBENEWSWIRE
1.00
0
10/02/2026
Biotecnologia
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
Fonte
OKYO Pharma LTD
Emittente
GLOBENEWSWIRE
1.00
0
30/01/2026
Biotecnologia
Medicina Salute Benessere
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
Fonte
OKYO Pharma LTD
Emittente
GLOBENEWSWIRE
1.00
0
28/01/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
OKYO Pharma Announces Successful Type C Meeting with the FDA
Fonte
OKYO Pharma LTD
Emittente
GLOBENEWSWIRE
1.00
0
23/01/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
Fonte
OKYO Pharma LTD
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0